630 related articles for article (PubMed ID: 28991932)
101. GLP-1 receptor agonists and cardiovascular outcome trials: An update.
Andrikou E; Tsioufis C; Andrikou I; Leontsinis I; Tousoulis D; Papanas N
Hellenic J Cardiol; 2019; 60(6):347-351. PubMed ID: 30528435
[TBL] [Abstract][Full Text] [Related]
102. Safety of Once-weekly Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.
Frias JP
J Fam Pract; 2018 Jun; 67(6 suppl):S25-S34. PubMed ID: 29912998
[TBL] [Abstract][Full Text] [Related]
103. Dulaglutide: A Review in Type 2 Diabetes.
Burness CB; Scott LJ
BioDrugs; 2015 Dec; 29(6):407-18. PubMed ID: 26423061
[TBL] [Abstract][Full Text] [Related]
104. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.
Dicembrini I; Nreu B; Scatena A; Andreozzi F; Sesti G; Mannucci E; Monami M
Acta Diabetol; 2017 Oct; 54(10):933-941. PubMed ID: 28748377
[TBL] [Abstract][Full Text] [Related]
105. Is it safe to acutely discontinue insulin therapy in patients with chronic hyperglycaemia starting GLP-1R agonists?
Okiro JO; Mc Hugh C; Abdalla A
BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28710307
[TBL] [Abstract][Full Text] [Related]
106. Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis.
Liu Y; Zhang X; Chai S; Zhao X; Ji L
J Diabetes Res; 2019; 2019():1534365. PubMed ID: 31396537
[TBL] [Abstract][Full Text] [Related]
107. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.
Montvida O; Klein K; Kumar S; Khunti K; Paul SK
Diabetes Obes Metab; 2017 Jan; 19(1):108-117. PubMed ID: 27629433
[TBL] [Abstract][Full Text] [Related]
108. GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
Simó R; Hernández C
Diabetes; 2017 Jun; 66(6):1453-1460. PubMed ID: 28533296
[TBL] [Abstract][Full Text] [Related]
109. Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
McReelis KD; Lovshin JA
Can J Ophthalmol; 2017 Nov; 52 Suppl 1():S4-S7. PubMed ID: 29074013
[No Abstract] [Full Text] [Related]
110. Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management.
Powell J; Taylor J
Clin Ther; 2024 Mar; 46(3):289-292. PubMed ID: 38310052
[TBL] [Abstract][Full Text] [Related]
111. Comparative Analysis of the Anti-Inflammatory Effects of Liraglutide and Dulaglutide.
Hou Y; Fan Y; Cheng Y; Peng X; Shan C; Yang Y
Int Heart J; 2024 May; 65(3):548-556. PubMed ID: 38749748
[TBL] [Abstract][Full Text] [Related]
112. Investigational glucagon-like peptide-1 agonists for the treatment of obesity.
Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
Expert Opin Investig Drugs; 2016 Oct; 25(10):1167-79. PubMed ID: 27563838
[TBL] [Abstract][Full Text] [Related]
113. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
Bettge K; Kahle M; Abd El Aziz MS; Meier JJ; Nauck MA
Diabetes Obes Metab; 2017 Mar; 19(3):336-347. PubMed ID: 27860132
[TBL] [Abstract][Full Text] [Related]
114. Adjunctive Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus.
Harris KB; Boland CL
Pharmacotherapy; 2016 Sep; 36(9):1011-20. PubMed ID: 27485823
[TBL] [Abstract][Full Text] [Related]
115. Two new GLP-1 receptor agonists for diabetes.
Med Lett Drugs Ther; 2014 Nov; 56(1455):109-11. PubMed ID: 25372847
[No Abstract] [Full Text] [Related]
116. Real-world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus.
Guo L; Xi Y; Li L; Guo K; Wu J; Xu J; Wang Y; Wu G; Si S
Diabetes Obes Metab; 2024 Jul; 26(7):2979-2983. PubMed ID: 38600796
[No Abstract] [Full Text] [Related]
117. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
[TBL] [Abstract][Full Text] [Related]
118. Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features.
Lyseng-Williamson KA
Clin Drug Investig; 2019 Aug; 39(8):805-819. PubMed ID: 31317516
[TBL] [Abstract][Full Text] [Related]
119. GLP-1 receptor agonists and heart failure in diabetes.
Scheen AJ
Diabetes Metab; 2017 Apr; 43 Suppl 1():2S13-2S19. PubMed ID: 28431666
[TBL] [Abstract][Full Text] [Related]
120. The role of glucagon-like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity-A systematic review.
Ng VWW; Gerard G; Koh JJK; Loke KY; Lee YS; Ng NBH
Clin Obes; 2024 Jun; 14(3):e12642. PubMed ID: 38273176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
